Atlas Venture Life Science Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History

Atlas Venture Life Science Advisors’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,412,560	Closed	-$59.8M	–	7
2025 Q4	$59.8M	Sell	6,412,560 -17,697	-0.3%	-$148K	6.91%	5
2025 Q3	$45.3M	Hold	6,430,257	–	–	6.02%	6
2025 Q2	$41.8M	Hold	6,430,257	–	–	6.31%	7
2025 Q1	$51M	Hold	6,430,257	–	–	9.77%	4
2024 Q4	$81.5M	Hold	6,430,257	–	–	9.94%	5
2024 Q3	$89.6M	Hold	6,430,257	–	–	8.3%	6
2024 Q2	$88.6M	Hold	6,430,257	–	–	9.33%	5
2024 Q1	$106M	Sell	6,430,257 -1,178,137	-15%	-$17.6M	9.8%	4
2023 Q4	$111M	Hold	7,608,394	–	–	13.23%	5
2023 Q3	$93.4M	Hold	7,608,394	–	–	14.46%	2
2023 Q2	$90.8M	Hold	7,608,394	–	–	11.31%	4
2023 Q1	$102M	Buy	7,608,394 +40,077	+0.5%	+$783K	13.77%	3
2022 Q4	$163M	Sell	7,568,317 -600,854	-7%	-$12.3M	19.62%	1
2022 Q3	$164M	Sell	8,169,171 -799,134	-9%	-$17M	18.06%	2
2022 Q2	$161M	Buy	8,968,305 +766,667	+9%	+$7.92M	26.84%	1
2022 Q1	$81.4M	Hold	8,201,638	–	–	10.29%	3
2021 Q4	$138M	Buy	+8,201,638	New	+$169M	12.69%	2

Other funds holding DAWN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Atlas Venture Life Science Advisors's DAWN Position: Q1 2026 in Review

Atlas Venture Life Science Advisors sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 6,412,560 shares — an estimated $59.8M sold.

Atlas Venture Life Science Advisors first reported a position in DAWN in Q4 2021 and held it in 17 quarters. The position peaked at $164M in Q3 2022. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

Atlas Venture Life Science Advisors reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
Atlas Venture Life Science Advisors sold 6,412,560 Day One Biopharmaceuticals shares in Q1 2026, an estimated $59.8M.
Atlas Venture Life Science Advisors first reported a position in Day One Biopharmaceuticals in Q4 2021 and held it in 17 quarters.
Atlas Venture Life Science Advisors's Day One Biopharmaceuticals position peaked at $164M in Q3 2022.
206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Atlas Venture Life Science Advisors's 13F filing for Q1 2026, filed 14 May 2026.